Investing carries serious risks, including partial or total loss of capital. Please read the Key Investment Information Sheet and the Risk factors and login before investing.

Presscuff 3A

The 1st Pressurized Endotracheal Tube
Key Investment Information Sheet Terms & Conditions
€301,000
total amount raised in round
244%
Financed 244%
  • Eligible for a tax reduction

Benjamin De Vlam

COO

Dr. Benjamin De Vlam is the COO of Presscuff. He is responsible for the day-to-day management of Presscuff.
He is a physician by training at the University of Antwerp.

Evert Van Meeuwen

CFO

Evert Van Meeuwen, CFA, is Presscuff's chief financial officer.

He has a background in investments and business development.

Emiel Suijs

Founder

Emiel Suijs is the inventor of the Presscuff. Throughout his working career, he has worked as a head nurse in the Intensive Care Unit of the VUB.

Peter Frederickx

Advisor

Peter Frederickx helps Presscuff achieve the necessary certification. He has years of experience as a lead auditor and has been helping companies meet the necessary MDR standards for many years now.

TAX SHELTER 45%

Investments in this company benefit from a 45% personal income tax reduction. Read more…
A remaining amount of €264,000 is available for the Tax Shelter benefit.

Raise summary

Crowd investments €61,000
Committed by others €240,000
Amount raised €301,000
Minimum round €25,000
Maximum round €2,500,000
Shares in the company (total round) 22.341%
Pre-money valuation €8,690,000
Post-money valuation min. €8,715,000
Post-money valuation max. €11,190,000